Indolent systemic mastocytosis: a case and review of the current available treatment options.

H Peter Soyer, Yvonne Lee, Peter Wood

Journal: Dermatology online journal 2014;19(6):18562

PMID: 24011312

Free Full Text on Arthur C Huntley MD, California Digital Library View on PubMed

Abstract

Mastocytosis denotes a heterogeneous group of disorders characterized by abnormal growth and accumulation of mast cells. Cutaneous mastocytosis is characterized by skin-limited disease and is the most common subtype. Systemic mastocytosis has extracutaneous organ involvement with variable symptomatology and prognosis. Clinical manifestations are secondary to mediator release or direct organ infiltration of mast cells. Current available treatment for systemic mastocytosis is non-curative with conventional symptom-directed therapy for all subtypes. Cytoreductive agents are available for those with refractory symptoms or extensive extracutaneous disease. To date, clinical responses remain mixed and systemic mastocytosis is still an incurable condition.

Address: Princess Alexandra Hospital, Brisbane, Queensland, Austrailia. [email protected]

Link outs

Free resources

Full Text Sources:

MeSH Terms: Adrenal Cortex Hormones, Adult, Bone Marrow, Calcium, Confusion, Contraindications, Disease Progression, Drug Therapy, Combination, Drugs, Investigational, Fatigue, Histamine Antagonists, Humans, Interferon-alpha, Male, Mast Cells, Mastocytosis, Systemic, Tryptases, Ultraviolet Therapy, Urticaria Pigmentosa, Vitamin D